Cranial suture obliteration is induced by removal of transforming growth factor (TGF)-β3 activity and prevented by removal of TCF-β2 activity from fetal rat calvaria in vitro

Journal of Craniofacial Genetics and Developmental Biology

Volumn 19, Issue 3, 1999, Pages 164-173

  Opperman, Lynne A ^a,c   Chhabra, Anikar ^a   Cho, Richard W ^b   Ogle, Roy C ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c BAYLOR COLLEGE OF DENTISTRY   (United States)

Author keywords

Calvaria; Craniosynostosis; Dura mater; Growth factors; Morphogenesis; Sutures

Indexed keywords

HEPARIN BINDING PROTEIN; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ANIMAL TISSUE; ARTICLE; BONE TISSUE; CALVARIA; CONTROLLED STUDY; CRANIAL SUTURE; DURA MATER; FETUS; FETUS DEVELOPMENT; HISTOLOGY; IN VITRO STUDY; MORPHOGENESIS; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; SKULL DEVELOPMENT; TISSUE CULTURE;

ANIMALS; ANTIBODIES; BINDING, COMPETITIVE; BONE DEVELOPMENT; CRANIOSYNOSTOSES; DURA MATER; FETUS; RATS; RATS, SPRAGUE-DAWLEY; SKULL; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA;

EID: 0032741235     PISSN: 02704145     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. ANDERSON J, BURNS HD, ENRIQUEZ-HARRIS P, WILKIE AOM, HEATH JK: Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. Human Molec Genet 7:1475-1483, 1998.
2. BAER MJ: Patterns of growth of the skull as revealed by vital staining. Hum Biol 26:80-126, 1954.
3. BELLUS GA, GAUDENZ K, ZACKAI EH, CLARKE LA, SZABO J, FRANCOMANO CA, MUENKE M: Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndromes. Nature Genet 14:174-176, 1996.
4. BOIVIN GP, O'TOOLE BA, ORMSHY IE, DIEBOLD RJ, EIS MJ, DOETSCHMAN T, KIER AB: Onset and progression of pathological lesions in transforming growth factor-β1-deficient mice. Am J Pathol 146:276-288, 1995.
5. BRESNICK SD SCHENDEL S: Growth factors in human craniosynostosis. 63rd Annual Scientific Meeting, ASPRS-PSEF-ASMS, September, 1994, San Diego, CA, pp. 41 42, 1994.
6. BRUNET CL, SHARPE PM, FERGUSON MW: Inhibition of TGF-β3 (but not TGF-β1 or TGF-β2) activity prevents normal mouse embryonic palate fusion. Int J Dev Biol 39:345-355, 1995.
7. BURGESS WH, MACIAG T: The heparin-binding (fibroblast) growth factor family of proteins. Ann Rev Biochem 58:575-606, 1989.
8. CARLTON MBL, COLLEDGE WH, EVANS MJ: Crouzon-like craniofacial dysmorphology in the mouse is caused by an insertional mutation at the Fgf3/Fgf4 locus. Dev Dynam 212:242-249, 1998.
9. COHEN MM, JR: Sutural biology and the correlates of craniosynostosis. Am J Med Genet 47:581-616, 1993.
10. D'AMORE P: Modes of FGF release in vivo and in vitro. Cancer Met Rev 9:227-238, 1990.
11. DENG GC, WYNSHAW-BORIS A, ZHOU F, KUO A, LEDER P: Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84:911-921, 1996.
12. ENLOW DH: Normal and abnormal patterns of craniofacial growth. In Persing JA, Edgerton MT, Jane JA (eds): "Scientific Foundations and Surgical Treatment of Craniosynostosis". Baltimore: Williams and Wilkins, pp. 83-86, 1989.
13. ERLEBACHER A, FILVAROFF EH, YE J-Q, DERYNCK R: Osteoblastic responses to TGF-β during bone remodeling. Molec Biol Cell 9:1903-1918, 1998.
14. GALVIN BD, HART KC, MEYER AN, WEBSTER MK, DONOGHUE DJ: Constitutive receptor activation by Crouzon syndrome mutations in fibroblast growth factor receptor (FGFR) 2. Proc Natl Acad Sci (USA) 93:7894-7899, 1996.
15. HORNER A, KEMP P, SUMMERS C, BORD S, BISHOP NJ, KELSALL AW, COLEMAN N, COMPSTON JE: Expression and distribution of transforming growth factor-beta isoforms and their signaling receptors in growing human bone. Bone 23:95-102, 1998.
16. HOWARD TD, PAZNEKAS WA, GREEN ED, CHIANG LC, MA N, ORTIZ DE LUNA RI, GARCIA DELGADO C, GONZALEZ-RAMOS M, KLINE AD, JABS EW: Mutations in TWIST, a basic helix-loop-helix transcription factor, in Sathre Chotzen syndrome. Nature Genet 15:36-41, 1997.
17. ISEKI S, WILKIE AOM, HEATH JK, ISHIMARU T, ETO K, MORRISS-KAY GM: Fgfr2 and osteopontin domains in the developing skull vault are mutually exclusive and can be altered by locally applied FGF2. Development 124:3375-3384, 1997.
18. JABS EW, MULLER U, LI X, MA L, LUO W, HAWORTH IS, KLISAK I, SPARKES R, WARMAN ML, MULLIKEN JB: A mutation in the homeodomain of the human msx2 gene in a family affected with autosomal dominant craniosynostosis. Cell 75:443-450, 1993.
19. JABS EW, LI X, SCOTT AF, MEYERS G, CHEN W, ECCLES M, MAO JI, CHARNAS LR, JACKSON CE, JAYE M: Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast receptor 2. Nature Genet 8:275-279, 1994.
20. KAARTINEN V, VONKEN JW, SHULER C, WARBURTON D, BU D, HEISTERKAMP N, GROFFEN J: Abnormal lung development and cleft palate in mice lacking TGF-β3 indicates defects of epthelial-mesenchymal interaction. Nature Genet 11:415-421, 1995.
21. KIM H-J, RICE DPC, KETTUNEN PJ, THESLEFF I: FGF-, BMP- and Shh-mediated signaling pathways in the regulation of cranial suture morphogenesis and calvarial bone development. Development 125:1214-1251, 1998.
22. KULKARNI AB, WARD JM, YASWEN L, MACKALL CL, BAUER SR, HUH C-G, GRESS RE, KARLSSON S: Transforming growth factor-β1 null mice. An animal model for inflammatory disorders. Am J Pathol 146:264-275, 1995.
23. LIN KY, NOLEN AA, JANE JA, GAMPPER TJ, OPPERMAN LA, OGLE RC: Elevated levels of transforming growth factor beta (TGF)-β2&3 in lambdoid sutures from children with persistent plagiocephaly. Cleft Palate-Craniofac J 34:331-337, 1997.
24. MCCAFFREY TA, FALCONE: DJ, DU B: Transforming growth factor-β1 is a heparin-binding protein: identification of putative heparin-binding regions and isolation of heparins with varying affinity for TGE-β1. J Cell Physiol 152:430-440, 1992.
25. MEYERS GA, ORLOW SJ, MUNRO JR, PRZYLEPA KA, JABS EW: Fibroblast growth factor receptor 3 (FGER3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nature Genet 11:462-464, 1995.
26. MUENKE M, SCHELL U, HEHR A, ROBIN NH, LOSKEN HW, SCHINZEL A, PULLEYN LJ, RUTLAND P, REARDON W, MALCOLM S: A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome. Nature Genet 8:269-274, 1994.
27. MUENKE M, GRIPP KW, MCDONALD-MCGINN DM, GAUDENZ K, WHITAKER LA, BARTLETT SP, MARKOWITZ RI, ROBIN NH, NWOKORO N, MULVIHILL JJ, LOSKEN HW, MULLIKEN JB, GUTTMACHER AK, WlLROY RS, CLARKE LA, HOLLWAY G, ADES LC, HAAN EA, MULLEY JC, COHEN MM, JR, BELLUS GA, FRANCOMANO CA, MOLONEY DM, WALL SA, WILKIE AO: A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome. Am J Hum Genet 60:555-564, 1997.
28. NAKAJIMA Y, YAMAGISHI T, NAKAMURA H, MARKWALD RR, KRUG EL: An autocrine function for transforming growth factor (TGF)-β3 in the transformation of atrioventricular canal endocardium into mesenchyme during chick heart development. Dev Biol 194:99-113, 1998.
29. NASKI MC, COLVIN JS, COFFIN JD, ORNITZ DM: Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development 125:4977-4988, 1998.
30. OPPERMAN LA, SAUNDERS TJ, BRUNS DE, BOYD JC, MILLS SE, BRUNS ME: Estrogen inhibits calbindin-D28k expression in mouse uterus. Endocrinology 130:1728-1735, 1992.
31. OPPERMAN LA, SWEENEY TM, REDMON J, PERSING JA, OGLE RC: Tissue interactions with underlying dura mater inhibit osseous obliteration of developing cranial sutures. Dev Dynam 198:312-322, 1993.
32. OPPERMAN LA, PASSARELLI RW, MORGAN EP, REINTJES M, OGLE RC: Cranial sutures require tissue interactions with dura mater to resist osseous obliteration in vitro. J Bone Min Res 10:1978-1987, 1995.
33. OPPERMAN LA, PASSARELLI RW, NOLEN AA, GAMPPER TJ, LlN KL, OGLE RC: Dura mater secretes soluble heparin-binding factors required for cranial suture morphogenesis. In Vitro Cell Dev Biol 32:627-632, 1996.
34. OPPERMAN LA, NOLEN AA, OGLE RC: TGF-β1, TGF-β2 and TGF-β3 exhibit distinct patterns of expression during cranial suture formation and obliteration in vivo and in vitro. J Bone Min Res 12:301-310, 1997.
35. PROETZEL G, PAWLOWSKI SA, WILES MV, YIN M, BOIVIN GP, HOWLES PN, DING J, FERGUSON MWJ, DOETSCHMAN T: Transforming growth factor-β3 is required for secondary palate fusion. Nature Genet 11:409-414, 1995.
36. REARDON W, WlNTER RM, RUTLAND P, PULLEYN LJ, JONES BM, MALCOLM S: Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nature Genet 8:98-103, 1994.
37. ROTH DA, LONGAKER MT, MCCARTHY JG, ROSEN DM, MCMULLEN HF, LEVINE JP, SUNG J, GOLD LI: Studies in cranial suture biology: Part I. Increased immunoreactivity for TGF-β isoforms (β1, β2 and β3) during rat cranial suture fusion. J Bone Min Res 12:311-321, 1997.
38. SANFORD LP, ORMSBY I, GITTENBERGER-DE GROOT AC, SARIOLA H, FRIEDMAN R, BOIVIN GP, CARDELL EL, DOETSCHMAN T: TGFβ2 knockout mice have multiple developmental defects that are non-overlapping with other TGFβ knockout phenotypes. Development 124:2659-2670, 1997.
39. TEN DIJKE P, IWATA KK, GODDARD C, PIELER C, CANALIS E, MCCARTHY TL, CENTRELLA M: Recombinant transforming growth factor type β3: biological activities and receptor-binding properties in isolated bone cells. Mol Cell Biol 10:4473-4479, 1990.
40. THOMAS JT, LIN K, NANDEDKAR M, CAMARGO M, CERVENKA J, LUYTEN FP: A human chondrodysplasia due to a mutation in a TGF-β superfamily member. Nature Genet 12:315-317, 1996.
41. WILKIE AOM, SLANEY SE, OLDRIDGF M, POOLE MD, ASHWORTH GJ, HOCKLEY AD, HAYWARD RD, DAVID DJ, PULLEYN LJ, RUTLAND P: Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nature Genet 9:165-172, 1995.